| The acute effects of HIV protease inhibitors on insulin suppression of glucose production in healthy HIV-negative men. | |
| | |
MedLine Citation:
|
PMID: 19680131 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: The effects of different HIV protease inhibitors (PIs) on peripheral insulin resistance have been described, but less is known about their effects on insulin suppression of endogenous glucose production (EGP). METHODS: We tested the acute effects of 3 PIs, indinavir, ritonavir, and amprenavir, on EGP quantified by stable isotope techniques during the hyperinsulinemic, euglycemic clamp in 3 similar placebo-controlled protocols. RESULTS: EGP was higher with indinavir in the hyperinsulinemic state than with placebo (4.1 +/- 1.3 vs. 2.2 +/- 0.8 microg x kg(-1) x min(-1), P = 0.04). A trend toward higher EGP was seen with ritonavir (3.6 +/- 0.3 vs. 3.0 +/- 0.5 microg x kg(-1) x min(-1), P = 0.08). There was no evidence that amprenavir blunted insulin suppression of EGP compared with placebo (2.9 +/- 0.04 vs. 3.2 +/- 0.7 microg x kg(-1) x min(-1), P = 0.63). CONCLUSIONS: Some PIs can acutely blunt the ability of insulin to suppress EGP, but, as with insulin resistance, the effects of PIs on EGP are drug-specific, not class-specific. |
| | |
Authors:
|
Grace A Lee; Jean-Marc Schwarz; Sophie Patzek; Seungki Kim; Artem Dyachenko; Michael Wen; Kathleen Mulligan; Morris Schambelan; Carl Grunfeld |
Publication Detail:
|
Type: Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Journal of acquired immune deficiency syndromes (1999) Volume: 52 ISSN: 1944-7884 ISO Abbreviation: J. Acquir. Immune Defic. Syndr. Publication Date: 2009 Oct |
Date Detail:
|
Created Date: 2010-02-01 Completed Date: 2010-02-16 Revised Date: 2011-09-26 |
Medline Journal Info:
|
Nlm Unique ID: 100892005 Medline TA: J Acquir Immune Defic Syndr Country: United States |
Other Details:
|
Languages: eng Pagination: 246-8 Citation Subset: IM; X |
Affiliation:
|
Department of Medicine, University of California, San Francisco, CA, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Carbamates
/
adverse effects* Glucose / metabolism* HIV Protease Inhibitors / adverse effects* Human Experimentation Humans Indinavir / adverse effects* Insulin / metabolism* Male Placebos / administration & dosage Ritonavir / adverse effects* Sulfonamides / adverse effects* |
| Grant Support | |
ID/Acronym/Agency:
|
DK54615/DK/NIDDK NIH HHS; DK66999/DK/NIDDK NIH HHS; R01 DK066999-01/DK/NIDDK NIH HHS; R01 DK066999-02/DK/NIDDK NIH HHS; R01 DK066999-03/DK/NIDDK NIH HHS; R01 DK066999-04/DK/NIDDK NIH HHS; R01 DK066999-05/DK/NIDDK NIH HHS; R01 DK066999-06/DK/NIDDK NIH HHS; R01 DK066999-07/DK/NIDDK NIH HHS; R01 DK066999-08/DK/NIDDK NIH HHS; RR00083/RR/NCRR NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/Carbamates; 0/HIV Protease Inhibitors; 0/Placebos; 0/Ritonavir; 0/Sulfonamides; 11061-68-0/Insulin; 150378-17-9/Indinavir; 161814-49-9/amprenavir; 50-99-7/Glucose |
| Comments/Corrections | |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Computer simulator among experts involved in screening colonoscopy.
Next Document: Transcatheter closure of coronary artery fistula using the new Amplatzer vascular plug and a telesco...